Affiliations: | 2014 | Biology, Molecular and Cellular | Harvard University, Cambridge, MA, United States |
Area:
Stem Cell, Neurodegenerative diseases
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Jackson L. Sandoe is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 2015 — 2016 |
Sandoe, Jackson L |
F32Activity Code Description:
To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Developin in-Vitro Models of a Beta Toxicity: Complementary Yeast and Human Stem Cell Approaches @ Whitehead Institute For Biomedical Res
? DESCRIPTION (provided by applicant): Developing In-Vitro Models of Aß Toxicity: Complementary Yeast and Human Stem Cell approaches over 5 million americans have been diagnosed with Alzheimer's disease (AD). This patient population is expected to increase in the coming years as the number of elderly individuals grows. In turn, this growing patient population confers a need for increased funding to treat and care for affected individuals. Currently, no available treatments can add five or more years of symptom-free life to an individual with AD. One major obstacle to the development of novel therapeutic compounds has been the inability to obtain the neural tissue types impacted by AD for study. To address this issue, many research groups have developed model in vitro systems which facilitate the study of the disease course. Our group has previously developed a Saccharomyces cerevisiae model of amyloid beta 42 (Aß42) toxicity. Aß42 is commonly thought to be the culprit which underlies the neuronal apoptosis which occurs during AD progression. This yeast model has been used in genetic screens and uncovered therapeutic targets which modulate Aß42 toxicity. AIM 1 of the current proposal is to further characterize these genetic modifiers through loss-of-function studies. While the tractability of yeast provides a powerful model for identifying novel therapeutic targets these targets must be confirmed in clinically relevant models before therapeutic testing can be contemplated. Recently, human embryonic stem (hES) cell derived neurons have proven to recapitulate important aspects of neurodegenerative disorders in an in vitro setting. Therefore, in AIM 2 I propose to establish a complimentary human stem cell model of Aß42 toxicity. Furthermore, in AIM 3 I will use the established human stem cell model to confirm our previous findings in yeast in clinically relevant cell types and probe the influence of ApoE genotype on Aß42 toxicity. Together, these studies will delve deeper into possible therapeutic targets for Aß42 toxicity which could lead to efficacious compounds in future small molecule screens.
|
0.904 |